IL143289A0 - Streptococcal c5a peptidase vaccine - Google Patents

Streptococcal c5a peptidase vaccine

Info

Publication number
IL143289A0
IL143289A0 IL14328999A IL14328999A IL143289A0 IL 143289 A0 IL143289 A0 IL 143289A0 IL 14328999 A IL14328999 A IL 14328999A IL 14328999 A IL14328999 A IL 14328999A IL 143289 A0 IL143289 A0 IL 143289A0
Authority
IL
Israel
Prior art keywords
streptococcal
scp
disclosed
infection
peptidase
Prior art date
Application number
IL14328999A
Other languages
English (en)
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of IL143289A0 publication Critical patent/IL143289A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Exposure Control For Cameras (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14328999A 1998-12-07 1999-12-03 Streptococcal c5a peptidase vaccine IL143289A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/206,898 US6355255B1 (en) 1998-12-07 1998-12-07 Streptococcal C5a peptidase vaccine
PCT/US1999/028826 WO2000034487A1 (en) 1998-12-07 1999-12-03 STREPTOCOCCAL C5a PEPTIDASE VACCINE

Publications (1)

Publication Number Publication Date
IL143289A0 true IL143289A0 (en) 2002-04-21

Family

ID=43662233

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14328999A IL143289A0 (en) 1998-12-07 1999-12-03 Streptococcal c5a peptidase vaccine
IL143289A IL143289A (en) 1998-12-07 2001-05-22 Vaccination against Streptococcus variant A5C

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143289A IL143289A (en) 1998-12-07 2001-05-22 Vaccination against Streptococcus variant A5C

Country Status (18)

Country Link
US (4) US6355255B1 (sl)
EP (3) EP1137785B8 (sl)
JP (2) JP5122703B2 (sl)
KR (1) KR100777502B1 (sl)
CN (2) CN1679929B (sl)
AT (2) ATE370237T1 (sl)
AU (2) AU779085B2 (sl)
BR (1) BRPI9915988B8 (sl)
CA (1) CA2354508C (sl)
CY (1) CY1106983T1 (sl)
DE (2) DE69936877T2 (sl)
DK (3) DK2308981T3 (sl)
ES (3) ES2401998T3 (sl)
IL (2) IL143289A0 (sl)
MX (1) MXPA01005757A (sl)
PT (3) PT1137785E (sl)
SI (2) SI2308981T1 (sl)
WO (1) WO2000034487A1 (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
WO2004094468A2 (en) * 2003-04-23 2004-11-04 Hansa Medical Ab Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
CN101107010A (zh) 2004-11-01 2008-01-16 布里格海姆妇女医院公司 经修饰的链球菌多糖及其用途
GB2428006A (en) * 2005-07-07 2007-01-17 Jevgenis Morov AMI-3 vaccine comprising group A Streptococcus pyogenes bacteria
US7596254B2 (en) * 2006-03-17 2009-09-29 William Marsh Rice University Intra-operative 3-D reconstruction of bone cement boli using X-rays
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008002472A2 (en) * 2006-06-23 2008-01-03 Danisco Us Inc., Genencor Division Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
US20080311129A1 (en) * 2006-11-02 2008-12-18 Camas Incorporated Adherence inhibitor directed to and method of making and using
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2144924B1 (en) * 2007-04-16 2016-05-11 MinervaX Aps Fusion protein vaccine
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
AR074273A1 (es) * 2008-11-05 2011-01-05 Wyeth Corp Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
HUE033071T2 (hu) 2010-06-04 2017-11-28 Wyeth Llc Vakcinakészítmények
DK3831406T3 (da) 2010-08-23 2024-06-17 Wyeth Llc Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
BR112014021658A2 (pt) 2012-03-09 2017-07-11 Pfizer composições de neisseria meningitidis e métodos das mesmas
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102746388B (zh) * 2012-07-02 2014-06-25 中山大学 一种链球菌保护性抗原C5a及其制备方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
KR101775093B1 (ko) 2016-05-31 2017-09-19 그린코스 주식회사 베타인살리실레이트와 폴리에틸렌글리콜을 포함하는 각질 용해 화장품 조성물, 그 제조 방법, 및 이를 포함하는 화장품
WO2018142280A2 (en) 2017-01-31 2018-08-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN106822885B (zh) * 2017-02-16 2020-06-30 清华大学 肺炎链球菌疫苗
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
CN109045292A (zh) * 2018-11-08 2018-12-21 山东大学 一种a群链球菌寡糖蛋白缀合物及其制备方法与应用
KR102165688B1 (ko) 2020-04-03 2020-10-14 주식회사 퀀타매트릭스 그람 양성균 배양용 배양액
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152411A (en) * 1977-07-27 1979-05-01 Akzona Incorporated High specific activity labeled substances
WO1980000412A1 (en) 1978-08-24 1980-03-20 N Gilmour Pasteurellosis vaccines
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4695562A (en) 1984-04-06 1987-09-22 Univ. Of Tennessee Research Corp. Synthetic peptide compounds
US4772584A (en) 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
EP0272929B1 (en) 1986-12-24 1996-03-20 Genentech, Inc. Enkephalinase for therapeutic use
US5124153A (en) 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5162226A (en) 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
WO1989009064A1 (en) 1988-03-25 1989-10-05 The Rockefeller University Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
US4863159A (en) 1988-03-25 1989-09-05 Morrison Molded Fiber Glass Company Apparatus for use in the exercise of the human body
WO1992002612A2 (en) 1990-07-31 1992-02-20 Genentech, Inc. Tissue plasminogen activator variants with decreased clearance
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
AU668908B2 (en) 1992-01-08 1996-05-23 Rockefeller University, The Multifunctional surface protein of streptococci
DE69332520T2 (de) 1992-03-09 2003-09-11 Cytel Corp., San Diego Nukleinsäure, expressionsvektor und zusammensetzungen zur identifizierung und herstellung von rekombinanten sialyltransferasen
WO1993021220A1 (en) 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
IL106922A (en) 1992-09-14 1998-08-16 Novartis Ag Complex materials with one or more wettable surfaces and a process for their preparation
AU5128493A (en) 1992-09-16 1994-04-12 University Of Tennessee Research Corporation, The Recombinant multivalent m protein vaccine
AU5128593A (en) 1992-09-16 1994-04-12 University Of Tennessee Research Corporation, The Antigen of hybrid m protein and carrier for group a streptococcal vaccine
US5866135A (en) 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5679654A (en) 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5618129A (en) 1995-03-13 1997-04-08 Paragon Electric Company, Inc. Snap-engaging mounting plate
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist

Also Published As

Publication number Publication date
AU2004231164B2 (en) 2008-05-01
CN100389198C (zh) 2008-05-21
SI2308981T1 (sl) 2013-04-30
EP1137785B8 (en) 2007-11-21
EP2308981B1 (en) 2013-02-13
ES2401998T3 (es) 2013-04-26
EP2308981A1 (en) 2011-04-13
KR100777502B1 (ko) 2007-11-16
AU2166500A (en) 2000-06-26
DK1137785T3 (da) 2007-12-10
BR9915988A (pt) 2001-09-04
PT2308981E (pt) 2013-02-21
US20040062777A1 (en) 2004-04-01
DE69936877T2 (de) 2008-04-30
ATE503017T1 (de) 2011-04-15
ES2293745T3 (es) 2008-03-16
AU2004231164A1 (en) 2004-12-09
BRPI9915988B1 (pt) 2015-08-18
US7635483B2 (en) 2009-12-22
BRPI9915988B8 (pt) 2021-05-25
US6951653B2 (en) 2005-10-04
US20050136068A1 (en) 2005-06-23
EP1137785B1 (en) 2007-08-15
CN1679929A (zh) 2005-10-12
DK2308981T3 (da) 2013-05-13
DK1892298T3 (da) 2011-06-14
CA2354508C (en) 2011-02-01
MXPA01005757A (es) 2002-04-24
EP1892298B1 (en) 2011-03-23
CY1106983T1 (el) 2012-09-26
JP2002531584A (ja) 2002-09-24
KR20010082326A (ko) 2001-08-29
EP1137785A1 (en) 2001-10-04
SI1892298T1 (sl) 2011-08-31
DE69943305D1 (de) 2011-05-05
EP1892298A1 (en) 2008-02-27
CA2354508A1 (en) 2000-06-15
WO2000034487A1 (en) 2000-06-15
IL143289A (en) 2011-11-30
ES2363446T3 (es) 2011-08-04
US20060153879A1 (en) 2006-07-13
US8440205B2 (en) 2013-05-14
PT1137785E (pt) 2007-10-22
JP2012072153A (ja) 2012-04-12
US6355255B1 (en) 2002-03-12
ATE370237T1 (de) 2007-09-15
DE69936877D1 (de) 2007-09-27
JP5122703B2 (ja) 2013-01-16
CN1679929B (zh) 2012-09-26
PT1892298E (pt) 2011-06-01
CN1329669A (zh) 2002-01-02
AU779085B2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
IL143289A0 (en) Streptococcal c5a peptidase vaccine
PT877624E (pt) Vacina de c5a peptidase estreptococica
EP2050464A3 (en) Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
DE69327534D1 (de) Impfstoffe gegen diphtherietoxin
HK1043943A1 (zh) 肺炎鏈球菌蛋白質和疫苗
PL304419A1 (en) Urease based vaccine against heliobacter infections
NZ507717A (en) Derivatives of pneumococcal choline binding proteins for vaccines
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
PL303482A1 (en) Vaccine against infection with streptococcus suis, streptococcus suis polypeptide and method of preparing such vaccine
TW275632B (sl)
AU2015095A (en) Mucosal administration of pneumococcal antigens
IL129366A0 (en) Helicobacter pylori live vaccine
IL141443A0 (en) Vaccine comprising cytokine-induced heat shock proteins (hsp)
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
MY153646A (en) A vaccine protecting against pig haemophilosis.
MX9604262A (es) Antigenos de pasteurellaceae y vacunas relacionadas.